Bard Receives FDA Clearance for Colorectal Stent.Health/Medical Writers MURRAY HILL, N.J.--(BW HealthWire)--April 25, 2000 C. R. Bard C. R. Bard, Inc. (NYSE: BCR) is one of the large S&P 500 companies of the United States, a surgical specialties and hospital medical device manufacturer in Murray Hill, New Jersey. It is named after its founder, who sold the company within only a few years of its founding. , Inc. (NYSE-BCR) announced today it has received U.S. FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. 510(k) concurrence to market the Bard Memotherm colorectal stent for treating malignant obstructions resulting from colon cancer colon cancer, cancer of any part of the colon (often called the large intestine). Colon cancer is the second most common cancer diagnosed in the United States. . The Memotherm colorectal stent will be marketed through Bard's Interventional Products division and will be available immediately. Worldwide, colorectal cancer strikes approximately 876,000 people each year, resulting in over 500,000 deaths. Colorectal cancer is the second leading cause of cancer related deaths in the United States for both men and women combined. Each year, approximately 140,000 new cases of colorectal cancer are diagnosed and 60,000 people die from the disease. Colorectal cancer surpasses both breast cancer and prostate cancer in mortality, and it is second only to lung cancer in number of deaths in the United States. The Bard Memotherm colorectal stent offers a minimally invasive alternative for managing patients with bowel obstruction due to malignant growths and strictures. This self-expanding nitinol stent is preloaded on a flexible delivery catheter and endoscopically placed into the colon, without any incisions or general anesthesia required. Once deployed in the area of obstruction, the "shape memory" of nitinol expands in response to body temperature and applies constant radial pressure to restore luminal patency pa·ten·cy n. The state or quality of being open, expanded, or unblocked. patency the condition of being open. and improve bowel function. "By eliminating the increased risks and costs associated with the traditional approach of multi-staged surgery with colostomy colostomy Surgical formation of an artificial anus by making an opening from the colon through the abdominal wall. It may be done to decompress an obstructed colon, to allow excretion when part of the colon must be removed, or to permit healing of the colon. , colorectal stenting offers significant advantages for both the patient and physician," stated William H. Longfield, chairman and chief executive officer. "By electively placing a colorectal stent to decompress To restore compressed data back to its original size. (compression, data) decompress - To reverse the effects of data compression. the colon prior to scheduled surgery, the patient's condition can be optimized and emergency surgical intervention avoided. In a cancer patient who is not a surgical candidate, a colorectal stent can be used palliatively, to avoid the need for a colostomy and significantly improve the patient's quality of life," Longfield concluded. C. R. Bard, Inc., headquartered in Murray Hill, New Jersey
|
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion